Department of Pharmacy, The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, China.
Department of Clinical Research, Guangdong Second Provincial General Hospital, Guangzhou, China.
J Clin Pharm Ther. 2022 Nov;47(11):1811-1819. doi: 10.1111/jcpt.13770. Epub 2022 Sep 13.
Olanzapine is an atypical antipsychotic drug used for mental disorders. There are limited studies providing sufficient pharmacokinetic data, thus the variability of concentrations of olanzapine used in Chinese paediatric patients aged 10 to 17 years remains to be evaluated.
Therapeutic drug monitoring data were collected from 151 paediatric patients aged 10 to 17 years who received olanzapine. The model was developed with a NONMEM software program. The final model validation and evaluation were assessed by bootstrap, diagnostic scatter plots, and normalized prediction distribution error (NPDE). Regimens of different dosages were simulated to reach the target concentration levels of 20 ng/ml, by using the final model with typical parameters.
The one-compartment model was considered the best fit for the data. Typical estimates of the absorption rate constant (Ka), apparent clearance (CL/F), and apparent distribution volume (V/F) in the final model were 0.142 h , 15.4 L/h, and 322 L, respectively. Sex and concomitant valproate (VPA) were included as significant predictors of olanzapine clearance, which was described by the following equation: CL/F = 15.4 × (1 + 0.546 × SEX) × (1 + 0.264 × VPA). Results of Monte-Carlo simulation suggested that male paediatric patients with concomitant VPA were advised to take no less than 15 mg per day of olanzapine orally, and in female paediatric patients with concomitant VPA, a dosing regimen of 10 mg may be sufficient to achieve the therapeutic range of olanzapine.
Our results identified concomitant valproate and sex as significant covariates in olanzapine population pharmacokinetics. Our model may be a useful tool for recommending dosage adjustments for physicians. The pharmacokinetics of olanzapine in patients aged 10 to 17 years was generally similar to that of adults and the elderly.
奥氮平是一种用于治疗精神障碍的非典型抗精神病药物。目前研究提供的药代动力学数据有限,因此,在中国 10 至 17 岁的儿科患者中使用奥氮平的浓度变化仍有待评估。
收集了 151 名接受奥氮平治疗的 10 至 17 岁儿科患者的治疗药物监测数据。使用 NONMEM 软件程序建立模型。通过自举法、诊断散点图和归一化预测分布误差(NPDE)评估最终模型的验证和评价。使用典型参数的最终模型,模拟不同剂量方案,以达到 20ng/ml 的目标浓度水平。
单室模型被认为是最适合该数据的模型。最终模型中吸收速率常数(Ka)、表观清除率(CL/F)和表观分布容积(V/F)的典型估计值分别为 0.142h、15.4L/h 和 322L。性别和合并使用丙戊酸钠(VPA)被纳入奥氮平清除率的显著预测因子,其描述方程为:CL/F=15.4×(1+0.546×SEX)×(1+0.264×VPA)。蒙特卡罗模拟结果表明,合并使用 VPA 的男性儿科患者建议每天口服奥氮平不少于 15mg,而合并使用 VPA 的女性儿科患者,10mg 的剂量方案可能足以达到奥氮平的治疗范围。
我们的结果确定合并使用丙戊酸钠和性别是奥氮平群体药代动力学的重要协变量。我们的模型可能是医生推荐剂量调整的有用工具。10 至 17 岁患者的奥氮平药代动力学与成人和老年人的药代动力学一般相似。